Gufic Biosciences' stock hits 52-week high after receiving CDSCO's approval for Isavuconazonium Sulfate API for Injection

12 Apr 2022 , 10:23 AM

Gufic Biosciences Limited has received permission for the sale and distribution of Isavuconazonium Sulfate API and finished formulation Isavuconazole for Injection 200 mg/vial from the Central Licensing Approving Authority, Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare for manufacture.

Isavuconazole for Injection of 200 mg/vial is said to provide treatment for Invasive Aspergillosis and Invasive Mucormycosis, to be used by people 18 years of age or above.

In general, Isavuconazole is a systemic antifungal drug of the triazole class. For this drug, Gufic has already received the USFDA approval on March 06, 2015, and European Medicines Agency’s (EMA) approval on October 15, 2015. It fights against Mucorales, Aspergillus, and other rare mould infections, enabling physicians to treat the patients without performing a confirmed diagnosis, the company said in the filing.

Gufic’s counter jumped to a new 52-week high in today’s trade at Rs283.65. It is currently trading at Rs276.30, up by 11.34% against its previous close of Rs248.15 on NSE.